GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

An antisense drug in development at GSK has shown further activity against hepatitis B virus (HBV) in a mid-stage trial, setting up a phase 3 assessment next year to see if it could offer a ...

GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen GSK announced its intention to open the Rockville vaccine R&D center back in 2015. The company first acquired ...